Quantisnow Logo
Dashboard
Subscribe to $FIXX

Homology Medicines Inc.

$FIXX
Biotechnology: Pharmaceutical Preparations
Health Care

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.

IPO Year: 2018

Exchange: NASDAQ

Website: homologymedicines.com

Peers

$AKUS
$VOR

Recent Analyst Ratings for Homology Medicines Inc.

DatePrice TargetRatingAnalyst
7/28/2023$9.00 → $1.50Outperform → Neutral
Robert W. Baird
2/28/2022$30.00 → $20.00Buy
HC Wainwright & Co.
2/22/2022$25.00 → $9.00Buy
B of A Securities
2/22/2022$35.00 → $29.00Neutral
BTIG Research
2/22/2022Outperform → Sector Perform
RBC Capital Mkts
2/22/2022$25.00 → $15.00Buy
Chardan Capital
2/22/2022$35.00 → $29.00Buy
BTIG
2/22/2022$30.00 → $4.00Outperform → Sector Perform
RBC Capital
2/22/2022Outperform → Perform
Oppenheimer
11/16/2021$30.00 → $25.00Buy
Chardan Capital
See more ratings

Homology Medicines Inc. Press Releases

Fastest customizable press release news feed in the world

See more

  • Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

    BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the "Gene Editing Corporate Panel" during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology's website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation. About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Homology Medicines to Participate at Upcoming Conferences

    BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT"Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic" panel featuring Dr. Seymour on October 11 at 4:00 p.m. PT"New Business Models for Manufacturing Investment" panel featuring Arthur Tzianabos, Ph.D., Chairman of the Board of Homology, on October 12 at 3:15 p.m. PT

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures

    SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa

    $AKUS
    $CINC
    $FIXX
    $IONS
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU

    BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: FASEB's The Genome Engineering Conference: Cutting-Edge Research and Applications on June 29, 2022 at 5:30 p.m. WET/12:30 p.m. ET in Lisbon, Portugal Homology will deliver an oral presentation titled, "Molecular Characterization of In Vivo Editing in Human Hepatocytes and a PKU Mouse Model using rAAVHSCs," which confirms the precision of homologous recombination-based integration of HMI-103 nuclease-free gene editing candidate for phenylketonuria (PKU) using genome-wide assays. 2022 NPKUA Confe

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting

    - Multiple Presentations Feature HMI-103 Phase 1 Investigational Therapy for PKU, Including Genome-Wide Integration Assays to Confirm No Off-Target Editing - - New Data from GTx-mAb Program Support Potential to Target Many Complement-Related Disorders - - Presentations Feature the Discovery and Characterization of a Non-Liver-Tropic Capsid and Other Distinct Properties of Homology's Family of 15 Naturally Derived AAVHSCs - - Symposium to be Held on May 18, 2022 at 7:30 a.m. ET - BEDFORD, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that the first presentation detailing the optimization and mechanism of act

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President

    BEDFORD, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., Chief Scientific Officer, has been promoted to President of Homology. In addition to his role as CSO, Dr. Seymour will assume broader responsibilities for additional functional areas, including human resources, clinical development and operations, and commercial strategy. "Albert has fostered a culture of scientific innovation and execution that brought our first gene therapy candidate to the clinic within three years from inception, and this was followed closely by two additional trial initiations, including our first nuclease

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

    - Formed New AAV Manufacturing and Innovation Business with Oxford Biomedica to Leverage Homology's Process Development and Manufacturing Capabilities - - Received $130 Million Non-Dilutive Capital that Significantly Extends Cash Runway - - Launched pheEDIT Gene Editing Trial for PKU and juMPStart Gene Therapy Trial for Hunter Syndrome; Program Updates Expected by Year-End - - Company Updates Guidance on pheNIX Gene Therapy Trial for PKU - BEDFORD, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2021, and highlighted recent accomplishm

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology

    Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the "Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with Homology Medicines Inc. (NASDAQ:FIXX) ("Homology"), a genetic medicines company, to establish Oxford Biomedica Solutions LLC, a new US-based full scope, Adeno-Associated Virus (AAV) manufacturing and innovation business. The new Oxford Biomedica Solutions business is fully operational and offers a proprietary ‘plug and play' platform that is capable of achie

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica

    BEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today the successful closing of the deal with Oxford Biomedica plc (LSE: OXB) to establish an Adeno-Associated Virus (AAV) Manufacturing and Innovation Business. The new company, Oxford Biomedica Solutions LLC, incorporates Homology's technical and manufacturing operations, team and GMP facility with OXB's extensive know-how in viral vector manufacturing. Homology will maintain access to the capabilities that the Company built over the past four years, as well as share in potential benefits derived from future innovations as a 20% owner and preferred customer of

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Homology Medicines to Participate in Upcoming Investor Conferences

    BEDFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences: Cowen 42nd Annual Health Care Conference: Corporate Panel Discussion – Gene Editing: March 8 at 12:50 p.m. ET Oppenheimer 32nd Annual Healthcare Conference: Fireside Chat: March 16 at 1:20 p.m. ET H.C. Wainwright Gene Therapy and Gene Editing Conference: Available on-demand March 30 at 7:00 a.m. ET The webcast presentations from the investor conferences will be accessible on Homology's website in the Investors section, and the webcast replays will be available on the website for 90 days fo

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

Homology Medicines Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

Homology Medicines Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

Homology Medicines Inc. SEC Filings

See more

Homology Medicines Inc. Leadership Updates

Live Leadership Updates

See more

  • Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

    - ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named Pr

    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

Homology Medicines Inc. Financials

Live finance-specific insights

See more

Homology Medicines Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more